Lartruvo

Active Ingredient(s): Olaratumab
FDA Approved: * October 19, 2016
Pharm Company: * ELI LILLY AND CO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Lartruvo Overview

Olaratumab is a monoclonal antibody which is being developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[1] In February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft tissue sarcoma.[2] In October 2016, the FDA issued an approval notice for use of olaratumab with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS).[3] Referen...

Read more Lartruvo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olaratumab

Recent Lartruvo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Olaratumab
  • Injection: 500mg/50ml, 500mg/50ml(10mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lartruvo: (1 result)

Sorted by National Drug Code
  • 0002-8926 Lartruvo 10 mg/ml Intravenous Solution by Eli Lilly and Company

Other drugs which contain Olaratumab or a similar ingredient: (1 result)